Roche buys precision medicine firm Ignyta for $1.7B

(By Anuja Vaidya for Becker’s Hospital Review)

Roche, a global pharmaceuticals and diagnostics company, is acquiring Ignyta for $27 per share in an all-cash transaction. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or


Leave a Reply